News - OxyDial Inc

Jan 2 2026

Agios’ AQVESME™ (mitapivat) Receives FDA Approval for Anemia in Thalassemia

The U.S. FDA has approved Agios Pharmaceuticals‘ AQVESME™ (mitapivat) for the treatment of anemia in adults with alpha- or beta-thalassemia. This approval, based on the positive Phase 3 ENERGIZE and …

OxyDial

Dec 29 2025

High-Dose Pociredir Data Show Stronger HbF Responses in Sickle Cell Disease

New Phase 1b data from Fulcrum Therapeutics suggest that higher doses of the investigational oral therapy pociredir may offer greater benefits for adults with sickle cell disease (SCD). In the …

OxyDial

Dec 18 2025

Motixafortide Data Points to More Accessible Gene Therapy Pathways in SCD

New clinical data from Ayrmid highlight a promising advance in stem cell mobilization for people with SCD pursuing gene therapy. In a first-in-human trial, the CXCR4 inhibitor motixafortide, alone and …

OxyDial

Dec 11 2025

Transdermal Curcumin Gel Shows Potential to Improve Cardiac Health in SCD Preclinical Study

New laboratory research from Vascarta Inc. highlights a novel approach to addressing SCD complications. The company’s investigational skin gel, VAS‑101, which contains the turmeric-derived compound curcumin, partially restored mitochondrial function …

OxyDial

Dec 5 2025

Novartis to Present Robust Hematology and Oncology Portfolio at Key Medical Conferences

Novartis announced it will present data from over 70 abstracts at the upcoming American Society of Hematology (ASH) Annual Meeting and San Antonio Breast Cancer Symposium (SABCS). Key highlights include …

OxyDial

Nov 26 2025

Agios’s Oral Therapy Mitapivat Meets Primary Goal in Phase 3 Sickle Cell Disease Trial

Agios Pharmaceuticals has announced positive top-line results from its Phase 3 RISE UP trial, demonstrating that its oral therapy, mitapivat, significantly increased hemoglobin levels in patients with sickle cell disease …

OxyDial

Nov 20 2025

Disc Medicine’s Therapy Enters Clinical Trial in SCD, Offering a Novel Approach to Iron Overload

Disc Medicine has initiated a Phase 1b clinical trial for DISC-3405, an investigational therapy designed to address iron overload in patients with sickle cell disease (SCD). The trial will evaluate …

OxyDial

Oct 29 2025

Counting Down to PACT Capital Conference 2025 – Join Us in Philadelphia This October!

We’re now just days away from the Mid-Atlantic Capital Conference, and the excitement at OxyDial continues to build as we prepare to take the stage on October 30th at the …

OxyDial

Oct 17 2025

OxyDial Shares Warm Thanks To the SAMB Community and Sponsors

OxyDial recently had the privilege to attend the Society for the Advancement of Patient Blood Management (SABM) Annual Meeting in Minneapolis, where we were warmly welcomed as a new member …